Últimas noticias sobre Seres Therapeutics (NASDAQ:MCRB) Bolsa

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

Following SER-155 administration, there was a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and a positive impact on biomarkers of systemic inflammation and immune homeostasis, in both cases as compared to placebo.

Biotech

News

Health Care

General

MCRB

Seres Therapeutics Announced New Translational Biomarker Results For Exploratory Endpoints From Its SER-155 Phase 1b Placebo-controlled Study In Patients Undergoing Allogenic Stem Cell Transplantation

WIIM

Seres Therapeutics shares are trading higher after the company announced that SER-155 received FDA breakthrough therapy designation for its bloodstream infection reduction.

Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) (Seres or the Company), a leading live biotherapeutics company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SER-155, the Company's lead investigational program, for the reduction of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies. In&nbsp;September 2024, Seres reported topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT, in which SER-155 was associated with a significant reduction in BSIs (77% relative risk reduction), a significant reduction in systemic antibiotic exposure, and lower incidence of febrile neutropenia, in each case as compared to placebo, through day 100 post-HSCT. Additionally, SER-155 was generally well tolerated, with no observed treatment-related serious adverse events.
FDA Breakthrough Therapy designation ensures communication and guidance from FDA to expedite the development of medicines which are intended to treat serious or life-threatening diseases, and in which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. The receipt of Breakthrough Therapy designation for SER-155, the Company's second program to receive such designation, grants Seres access to FDA senior management and a commitment from FDA to work closely with the Company, facilitating an efficient drug development process. In December 2023, SER-155 <a href="https://www.globenewswire.com/Tracker?data=6ctF6iOdNMFEAO4mU8cfdZ4pI6IUQ-05slSGi1GZR-krwnlLTUIXTNFHlfghiGOpxYH39ym-OTaUdO88CRjc3lYQY03IEXiEYqCwvYgqAYg3z3JRguywGQeKl5ZFHU-ZiPWnq9iPoK3U0JODzkeXzuYyF9lw8whlrm5tKRwuTU7pblQdB5wD2KRb4kcC_WtgeTF1cqc_GGOm25GVJZ87KG5OuGK2sMj1HRiTXcGZKE_Lu4OEJRe_t6ITy4utCZRC">received FDA Fast Track designation</a> for reducing the risk of infection and GvHD in this patient population.

Government

Regulations

Seres Therapeutics' SER-155 Receives FDA Breakthrough Therapy Designation for Bloodstream Infection Reduction

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $1.25 price target.

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.25) by 32 percent. This is a 3.13 percent decrease over losses of $(0.32) per share from the same period last year.

Earnings

Seres Therapeutics Q3 2024 GAAP EPS $(0.33) Misses $(0.25) Estimate, Seres Had $66.8M In Cash And Cash Equivalents, That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Seres Therapeutics will report an earnings per share (EPS) of $-0.24.
Seres Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.05 in the last quarter, leading to a 9.07% increase in the share price on the following day.
Here's a look at Seres Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.50</td>
<td>-0.50</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.22</td>
<td>-0.27</td>
<td>-0.32</td>
<td>-0.37</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>37.0%</td>
<td>-5.0%</td>
<td>39.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731430900_0.png" alt="eps graph" />
<h3>Market Performance of Seres Therapeutics's Stock</h3>
Shares of Seres Therapeutics were trading at $0.6917 as of November 11. Over the last 52-week period, shares are down 46.78%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MCRB/earnings">To track all earnings releases for Seres Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Seres Therapeutics's Earnings Preview

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero </a>downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight. Seres Therapeutics shares closed at $0.7570 on Wednesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Overweight to Neutral and lowered the price target from $230 to $210. Avery Dennison shares closed at $207.65 on Wednesday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Neutral and announced a $340 price target. Icon shares closed at $280.76 on Wednesday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Andrew Wittmann downgraded WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Outperform to Neutral and maintained the price target of $42. WillScot shares closed at $37.83 on Wednesday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel downgraded the rating for Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) from Overweight to Sector Weight. Verizon shares closed at $42.86 on Wednesday. <a href="https://www.benzinga.com/quote/VZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png" alt="" class="wp-image-611788" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233.png 1262w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ICLR

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

JP Morgan analyst Tessa Romero downgrades Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight.

Downgrades

JP Morgan Downgrades Seres Therapeutics to Underweight

Rumors

Watching Seres Therapeutics; Traders Circulate M&A Blog Unconfirmed Rumor That Nestle Has Said To Have Made A Bid Between $6.90-$7.20/Share

Members of the Board,
We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Science.
We have read a recent media report from Betaville which states that Nestlé S.A. ("Nestlé") approached Seres in July 2024 with an offer to acquire the entire Company for between $6.00 and $6.50 a share. Furthermore, the article states that Seres' Board rejected the offer and instead pursued the sale of the VOWST assets, which was initially announced in June 2024.
This concerns us because Nestlé's offer would have represented a more than 622% premium to the Company's stock price.1 Additionally, it is well known that Seres has been struggling to fund its operations. Investors do not appear to have strong confidence in the Company's ability to turn itself around in the public market, as evidenced by the negative stock price reaction to the August 6, 2024 announcement of the signing of the VOWST sale agreement.2 Nestlé's reported offer could have resulted in a superior outcome for stockholders than the VOWST sale, giving certainty of value to your investors.
If this media report is accurate, that would mean the Board violated its fiduciary duty to stockholders – specifically, its duty to maximize stockholder value – and could be held legally liable. We acknowledge that this information stems from a singular media report, which is why we are asking the Board to provide stockholders with a factual assessment of the contents of the report so that we may make fully informed decisions regarding our investment in the Company.
If you do not address my concerns in a timely fashion, we plan to consider all legal remedies under U.S. federal securities laws, which may potentially include asking a court to void the votes of the Special Meeting of Stockholders based on misleading and incomplete information given to investors.
Time is of the essence, as Seres intends to close the VOWST sale to Nestlé on September 30, 2024. We look forward to hearing from you soon.
Sincerely,
Lucien Selce
&nbsp;
Antoine Khalife
&nbsp;
&nbsp;
MKT Capital Ltd.

Seres Therapeutics Stockholders Publish Open Letter To Board Urging Clarity On Alleged Rejected Nestlé Takeover Offer Of $6.00-$6.50 Per Share Ahead Of VOWST Sale Closing

Seres Therapeutics shares are trading higher after the company announced its stockholders voted to approve the previously announced proposed sale of its VOWST business to Société des Produits Nestlé S.A.

<h3>Gainers</h3>
<ul>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 16.8% to $0.29 during Thursday's after-market session. The company's market cap stands at $6.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 6.69% to $6.16. The market value of their outstanding shares is at $3.1 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 6.01% to $0.88. The company's market cap stands at $134.0 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 5.88% to $1.08. The company's market cap stands at $6.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 5.4% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 5.2% to $0.26. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 27.8% to $0.33 during Thursday's after-market session. The company's market cap stands at $15.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 15.34% to $3.81. The market value of their outstanding shares is at $50.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 7.04% to $3.7. The market value of their outstanding shares is at $6.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 6.17% to $0.21. The company's market cap stands at $13.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 5.38% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares declined by 5.12% to $14.27. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIVI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CHRO

CPHI

LIPO

NVNO

STRM

TBIO

TCBP

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Seres Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.

Seres Therapeutics Stockholders Approve Sale Of VOWST To Nestlé Health Science; Sale Expected To Close on September 30

Watching Seres Therapeutics; Traders Circulate Unconfirmed M&A Blog Comments Suggesting Nestle Has Offered To Acquire The Company For $750M, Or $6-$6.50/Share

Seres Therapeutics Shares Halted To The Upside; Up 20.00%

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price target of $10....

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Latest data shows the largest indicative borrow rate increases among liquid option names include: Poet Technologies (POET) 35.27% +2.86, Heron Ther...

Largest borrow rate increases among liquid names

Seres Therapeutics (MCRB) announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to SER-155, the Company's...

Seres Therapeutics granted Breakthrough Therapy designation for SER-155

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Seres Therapeutics (MCRB – Research Report). The associated price targ...

Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence

Xilio Therapeutics (XLO) announced the appointment of Caroline Hensley as chief legal officer. Hensley most recently served as senior vice presiden...

Xilio Therapeutics appoints Caroline Hensley as CLO

Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President an...

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled stud...

Seres announces new translational biomarker results from SER-155 Phase 1b study

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Seres Therapeutics (MCRB – Research Report). The company's shares...

Seres Therapeutics (MCRB) Receives a Buy from TD Cowen

AGEN

AGIO

AXSM

CMRX

CYCC

HRTX

IPHA

IPHYF

MAXN

NKLA

POET

RIGL

SNDX

SWTX

XFOR

Press Releases

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Contracts

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Comments

Seres Therapeutics

Noticias

Últimas noticias sobre Seres Therapeutics (NASDAQ:MCRB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL